Protara Therapeutics (NASDAQ:TARA - Get Free Report)'s stock had its "buy" rating reiterated by HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $23.00 price objective on the stock.
Separately, Oppenheimer lowered their price objective on Protara Therapeutics from $30.00 to $25.00 and set an "outperform" rating on the stock in a research note on Monday, August 12th.
View Our Latest Analysis on TARA
Protara Therapeutics Stock Down 3.3 %
Protara Therapeutics stock traded down $0.09 during trading hours on Thursday, hitting $2.60. The stock had a trading volume of 140,641 shares, compared to its average volume of 216,636. Protara Therapeutics has a fifty-two week low of $1.04 and a fifty-two week high of $5.24. The company has a market cap of $53.64 million, a PE ratio of -0.95 and a beta of 1.77. The company has a 50-day moving average of $2.02 and a two-hundred day moving average of $2.29.
Insider Buying and Selling
In related news, major shareholder Opaleye Management Inc. sold 32,600 shares of the stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $1.71, for a total transaction of $55,746.00. Following the sale, the insider now directly owns 51,500 shares in the company, valued at $88,065. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 12.50% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the company. Oppenheimer & Co. Inc. acquired a new position in Protara Therapeutics during the 1st quarter worth $40,000. Marshall Wace LLP acquired a new position in Protara Therapeutics during the 2nd quarter worth $161,000. Renaissance Technologies LLC lifted its stake in shares of Protara Therapeutics by 77.8% in the 2nd quarter. Renaissance Technologies LLC now owns 150,400 shares of the company's stock valued at $313,000 after purchasing an additional 65,800 shares during the period. Ikarian Capital LLC lifted its stake in shares of Protara Therapeutics by 7.4% in the 1st quarter. Ikarian Capital LLC now owns 202,701 shares of the company's stock valued at $813,000 after purchasing an additional 14,037 shares during the period. Finally, CVI Holdings LLC acquired a new position in shares of Protara Therapeutics in the 2nd quarter valued at $630,000. Institutional investors and hedge funds own 38.13% of the company's stock.
Protara Therapeutics Company Profile
(
Get Free Report)
Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Featured Articles
Before you consider Protara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protara Therapeutics wasn't on the list.
While Protara Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
